Feature | May 30, 2014

Study Finds Bariatric Surgery Prevents Obese Patients From Developing Atrial Fibrillation

First-of-its-kind results presented at Heart Rhythm 2014 shows positive correlation between weight loss surgery and reduced risk of atrial fibrillation

May 30, 2014 — New research has found that bariatric surgery is an effective way to control weight in morbidly obese patients who are at risk for developing atrial fibrillation (AF). Bariatric or weight loss surgery is an operation on the stomach that limits food intake and is typically recommended for patients who are unable to lose weight on their own through diet and exercise.

The first study of its kind to look at the relationship between AF and bariatric surgery on a large patient population was presented at Heart Rhythm 2014, the Heart Rhythm Society’s (HRS) 35th annual scientific sessions.

According to the Centers for Disease Control and Prevention, more than two-thirds of the adult population in the United States is considered to be overweight or obese. Obesity is a known risk factor for arrhythmias like AF, and other risk factors for AF include smoking, high blood pressure and high cholesterol. AF is the most common arrhythmia and affects more than 2.7 million American adults. It is characterized by a rapid and irregular heartbeat when the top chambers of the heart (the atria) quiver (fibrillate) erratically, sometimes faster than 300 times per minute.

“Obesity has become an epidemic in our culture and prevention efforts are more important now than ever,” said Yong-Mei Cha, M.D., FHRS, professor of medicine at Mayo Clinic. “Bariatric surgery is a preventative measure that obese patients may choose to take, and our study shows that the surgery helps them not only lose weight, but also reduces their risk of developing a serious cardiac condition like AF. It is important to continue the conversation about how to help prevent this epidemic from becoming even more widespread.”

The retrospective study was conducted in 438 patients with a body mass index (BMI) of 40 or higher and identified as good candidates for bariatric surgery. Of these patients, 326 elected to undergo surgery for weight reduction and 112 were controls who were managed medically. The diagnosis of AF was documented by electrocardiogram (ECG) or ambulatory monitors and metabolic profiles were collected at baseline and follow-up.

The baseline BMI was different in the patients that underwent surgery versus those who did not have surgery (46.9 vs. 43.2kg/m2). The prevalence of AF at baseline was not significantly different between the two groups (surgical 3.7 percent vs. control 4.5 percent p=0.63) at baseline. After a mean follow-up duration of 7.2±3.7 years, new onset of AF occurred in 3.1 percent of the surgical group, significantly lower than 12.5 percent (p<0.01) in the medically treated group. Additionally, the surgical group had a significant reduction in BMI and improvement in metabolic profile compared to the control group.

For more information: www.hrsonline.org

Related Content

ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting| November 01, 2016
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...
Overlay Init